Cellectis Inc.

Good day, everyone, and welcome to today's Selective Second Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. you may withdraw yourself from the queue by pressing star two. Please note this call may be recorded and I'll be standing by should you need any assistance. It is now my pleasure to turn the conference over to Arthur Strill, Interim Chief Financial Officer. Please go ahead.

Good morning and welcome everyone to Selectus' second quarter 2025 business update and financial results conference call. Joining me on the call today are Dr. André Choulika, our Chief Executive Officer, and Dr. Adrian Kilcoyne, our Chief Medical Officer. Yesterday evening, Selectus issued a 6K in press release reporting our financial statements for the six-month period ended June 30, 2025, and a business update. The report and press release are available on our website at selectus.com. As a reminder, We will make statements regarding Selectasys financial outlook, including the presentation of our Bally 01 and Natalie 01 clinical trials, the timing and ability to progress our clinical trial into a later phase, the progress of our R&D activities under the AstraZeneca partnership, the timing and outcome of our arbitration with Servier, and sufficiency of cash to fund operations. These forward statements, which are based on our management's current expectations and assumptions, and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risk and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Security Exchange Commission, SEC, and the financial report, including the management report, for the year ended on December 31, 2024, and subsequent filings Selectus makes with the SEC from time to time. I would now like to turn the call over to Andre.

Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. I'd like to begin this call with an important announcement. On October the 16th, 2025, Selectus will be hosting an Investors R&D Day in New York City. Our leadership team, along with key opinion leaders, will present the phase one data set and late stage development strategy for last May cell, UCAR T22, in relapsed or refractory acute lymphoblastic leukemia. And we'll share insights on the company's vision and differentiated capabilities. Selectus Investors R&D Day is scheduled as an in-person only event. However, The recording of the event will be made available in the following days after the event. Despite the challenges of the biotech markets, our teams have remained focused on advancing research and developing solutions for patients with unmet medical needs. In July 2025, Selectus completed end of phase one discussion with both the United States Food and Drug Administration and European Medicine Agency. We're excited to prepare for the initiation of epivocal phase two trial for lasmosis cell, UCAR T22, in relapsed or refractory acute lymphoblastic leukemia in the second half of this year. Regarding the Nathalie 01 study, which is assessing eticelle product, UCAR T20 by 22, in relapsed or refractory not-Hodgkin's lymphoma, practice anticipates presenting data from phase one and outlining its late-stage development strategy late 2025. On the partnership front, research and development activities are ongoing under the three cell and gene therapy programs under our joint research and collaboration agreement with AstraZeneca. one allogenic CAR-T for myelotological malignancies, one allogenic CAR-T for solid tumors, and one in vivo gene therapy for genetic disorder. Regarding our licensing agreement involving Servier and sublicensee Allogene, and following Servier's decision in September 2022 to seize the development of the licensed CD19 products, We've initiated an arbitration before the Paris Mediation and Arbitration Center to protect our interests. We're asking the tribunals to terminate the agreement with Servier and to award fair compensation for the losses incurred due to the lack of development of the licensed products and the payment of the milestone, which we consider due under the agreement. The arbitral decision is expected to be rendered on December the 15th, 2025 or before. Earlier this quarter, Selectus announced that during its annual shareholders meeting, Mr. Andre Muller has been appointed as a member of the company's board of director. I'm pleased to welcome Andre at Selectus board. His extensive experience will be an invaluable asset to the company. We would also like to express our gratitude to Mr. Pierre Bastide and Mr. Axel Sven Malkamas, who have terminated their directorship for their esteemed commitment to Selectus. It has been a huge honor and a pleasure for us all to work with them during their term. Their contribution over the past years has been exceptional, and their precious support has greatly contributed to the advancement of the company's strategy. With that, I would like to turn the call over to Dr. Adrienne Kilcoyne, our Chief Medical Officer, who will give an overview of her clinical trials. Adrienne, please go ahead.